SANOCHEMIA Pharmazeutika AG: Advancement of Tolperisone's clinical development

Wien (pta022/19.01.2017/11:09 UTC+1) Sanochemia announces advancement of Tolperisone's clinical development by Neurana Pharmaceuticals Inc. in the USA
Vienna, January 19, 2017 - Sanochemia Pharmazeutika AG, Vienna (ISIN AT0000776307 ISIN DE000A1G7JQ9) announces that its strategic U.S. partner Neurana Pharmaceuticals Inc. (former Katama Pharmaceuticals) successfully secured initial financial investment for the advancement of clinical development of tolperisone in the USA.

Tolperisone is developed for the treatment of acute muscle spasms and spasticity. Neurana will start a clinical Phase I trial with a highly purified form of tolperisone HCl (NR100) in the summer of 2017. The Phase I trial aims to confirm the non-sedating properties of tolperisone in comparison to competitors.

Sanochemia received the first milestone payment from Neurana Pharmaceuticals as part of the strategic collaboration.
Christina Abrahamsberg, CSO of Sanochemia Pharmazeutika AG said "We are excited that the clinical Phase I trial with the highly purified tolperisone formulation will start soon and the development program of tolperisone is moving ahead".
Klaus Gerdes, CMO of Sanochemia Pharmazeutika AG said "We are committed to work together with Neurana Pharmaceuticals to ensure clinical development and commercialization of tolperisone in the US".
-------------------------------------------------------------------------------------------------------
About Tolperisone: Tolperisone is a skeletal muscle relaxant that is used for symptomatic treatment of acute and painful muscle spasms and spasticity. Tolperisone-containing medicines are widely used in several countries of the European Union. Tolperisone exerts its effects by a unique mechanism comprising muscle tone relief and analgesic effects. In the USA, tolperisone is a "New Chemical Entity" (NCE) and is currently being developed for the treatment of acute muscle spasms and spasticity by Sanochemia`s strategic partner Neurana Pharmaceuticals Inc.
About Neurana Pharmaceuticals Inc.: Neurana Pharmaceuticals is a privately held San Diego, CA based specialty pharmaceutical company employing a strategy to develop therapeutic products to treat unmet needs in diseases and conditions of the Central Nervous System. Neurana is the exclusive licensee to develop and commercialize the highly purified tolperisone HCl in North America for which a composition of matter patent was issued in 2016.

(end)

Emitter:	SANOCHEMIA Pharmazeutika AG Boltzmanngasse 11 1090 Wien Austria
Contact Person:	Bettina Zuccato
Phone:	+43 1 3191456-336
E-Mail:	b.zuccato@sanochemia.at
Website:	www.sanochemia.at
ISIN(s):	AT0000776307 (Share) DE000A1G7JQ9 (Bond)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Munich, Stuttgart; Vienna Stock Exchange (mid Market)